VetBridge Product Development Subsidiary I v. NewMarket Pharmaceuticals, LLC

CourtDistrict Court, W.D. Missouri
DecidedDecember 4, 2018
Docket5:18-cv-06147
StatusUnknown

This text of VetBridge Product Development Subsidiary I v. NewMarket Pharmaceuticals, LLC (VetBridge Product Development Subsidiary I v. NewMarket Pharmaceuticals, LLC) is published on Counsel Stack Legal Research, covering District Court, W.D. Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
VetBridge Product Development Subsidiary I v. NewMarket Pharmaceuticals, LLC, (W.D. Mo. 2018).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF MISSOURI ST. JOSEPH DIVISION

VetBridge Product Development Subsidiary I ) (NM-OMP), LLC, ) ) Plaintiff, ) ) v. ) Case No. 5:18-CV-06147-BCW ) NewMarket Pharmaceuticals, LLC, ) ) Defendant. )

ORDER Before the Court is Defendant’s motion to change venue (Doc. #8). The Court, being duly advised of the premises, denies said motion. BACKGROUND This matter arises out of a contractual breach alleged by Plaintiff VetBridge Product Development Subsidiary (“VetBridge”) against NewMarket Pharmaceuticals, LLC (“NewMarket”). VetBridge is a limited liability company, organized and existing under the laws of the State of Missouri with its principal place of business in St. Joseph, Missouri. VetBridge is involved in the marketing, sale, and distribution of animal healthcare products. NewMarket is a limited liability company, organized and existing under the laws of Delaware and based in Trenton, New Jersey. NewMarket is the owner of a new animal drug (“Product”) that it wants to market. Before doing so, NewMarket must first obtain an approval from the Food and Drug Administration for Veterinary Medicine (“FDA / CVM”). In July 2014, VetBridge and NewMarket entered into an Exclusive Distribution and License Agreement (“Agreement”). Under the Agreement, VetBridge agreed to provide $4 million in funding for the Product approval process in return for a license to distribute the Product within specified territory, after the approval by FDA / CVM. As relevant for purposes of the instant motion, the Agreement contained a “change of control” provision, contemplating that VetBridge would step into the shoes of and assume NewMarket’s beneficial position to make and commercialize the Products in the specified territory in the event NewMarket transfers more than

50% of its beneficial interest or substantially all of its assets relating to the Agreement. The Agreement also contained a forum selection clause, identifying the Western District of Missouri for any case where a party reasonably determines that injunctive relief is needed, and a choice of Missouri law clause. VetBridge furnished the contracted funding of $4 million in November 2015. In December 2014, NewMarket entered into a separate contract with VetPharm, Inc. (“VetPharm”),1 a New York corporation, to provide clinical trial services (“Data”) related to the testing of the Product required for purposes of the FDA / CVM approval (“VetPharm Contract”). The VetPharm Contract contained an arbitration clause. Because of a dispute between NewMarket and VetPharm over a fee payable for the Data under the Contract, VetPharm filed for arbitration

on March 8, 2017. On March 21, 2017, NewMarket brought an action against VetPharm in the District Court of New Jersey, alleging breach of contract, misappropriation of trade secrets and seeking a temporary restraining order (“TRO”) compelling VetPharm to provide the Data (“New Jersey Action”). VetPharm filed a cross-motion to stay the New Jersey Action and compel arbitration, which the New Jersey court granted. However, VetPharm voluntarily withdrew from arbitration on October 13, 2017. NewMarket moved to lift the stay in the New Jersey Action and re-applied for a TRO. VetPharm again moved to stay the New Jersey Action for a second time in favor of arbitration. Currently, NewMarket’s application for a TRO (now a preliminary injunction)

1 VetPham is not in any way related to VetBridge. and VetPharm’s second cross-motion to compel arbitration have been fully briefed and are awaiting a ruling from the New Jersey Action court. In the meantime, in May 2016, NewMarket informed VetBridge that it transferred an 80% ownership interest in NewMarket to a third party and also assigned its manufacturing rights and transferred the IP / Patent Rights to an unnamed overseas company for tax purposes, triggering the

“change of control” provision. On August 12, 2017, VetBridge filed a petition in the Circuit Court of Buchanan County, Missouri, against NewMarket, alleging claims for breach of contract, specific performance of the Agreement’s “change of control” provisions, and a preliminary and permanent injunction. NewMarket removed the action to this Court on October 5, 2018. In the instant motion, Defendant moves the Court to change venue to the District Court of New Jersey under the first-filed rule. DISCUSSION A. THE FIRST-FILED RULE DOES NOT APPLY.2 The “first-filed” rule “gives priority, for purposes of choosing among possible venues when

parallel litigation has been instituted in separate courts, to the party who first establishes jurisdiction.” Nw. Airlines, Inc. v. Am. Airlines, Inc., 989 F.2d 1002, 1006 (8th Cir. 1993). The rule is “not intended to be rigid, mechanical, or inflexible[.]” Orthmann v. Apple River Campground, Inc., 765 F.2d 119, 121 (8th Cir. 1985). What constitutes parallel litigation is not limited to actions between the same parties with identical claims. Hynes Aviation Indus., Inc. v. Sacramento E.D.M., Inc., No. 6:12-CV-03521-BCW, 2013 WL 12198837, at *2 (W.D. Mo. Aug.

2 While the parties argue the applicability of the first-filed rule, they also rely on 28 U.S.C. § 1404(a) for the change- of-venue analysis. The Court notes that the first-filed rule is different from § 1404(a). Advanced Physical Therapy, LLC v. Apex Physical Therapy, LLC, No. 17-3149-CV-S-BP, 2017 WL 9717215, at *2 (W.D. Mo. July 6, 2017) (“the first-filed rule is not based on § 1404(a)”). The Court will analyze the §1404(a) factors under the exceptions to the first-filed rule below. 1, 2013). However, the interests of the parties must be aligned. Id. The rule applies when the issues between the two litigations substantially overlap. Monsanto Tech. LLC v. Syngenta Crop Prot. Inc., 212 F. Supp. 2d 1101, 1103 (E.D. Mo. 2002). NewMarket moves the Court to transfer this matter to the District Court of New Jersey, asserting the New Jersey Action is a parallel first-filed action involving substantially overlapping

issues, because NewMarket’s breach of the Agreement relating to the FDA / CVM approval was caused by VetPharm’s failure to provide the Data required for the approval. VetBridge opposes the motion, arguing that the New Jersey Action is not parallel, because VetBridge is not a party to the New Jersey Action or the underlying VetPharm Contract and because its interests are not aligned with those of VetPharm. VetBridge further argues that any issues of VetPharm’s liability to NewMarket for failure to deliver the Data are unrelated to VetBridge’s claims against NewMarket for breach of contract claims in this action for failure to provide required funding and misuse of VetBridge’s investment and specific performance claim under the Agreement’s “change of control” provisions.

The Court agrees with VetBridge’s arguments and finds that the New Jersey Action is not parallel, for the reasons proffered by VetBridge. Scottsdale Ins. Co. v. Detco Indus., Inc., 426 F.3d 994, 997 (8th Cir. 2005) (issues in a tort action did not substantially overlap with issues in a separate insurance coverage action, because “although . . . the issues in each proceeding may depend on some of the same facts, that circumstance does not compel a conclusion that the suits are parallel, for the [other] court proceedings involve parties, arguments, and issues different from those in the[se] proceedings.”).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
VetBridge Product Development Subsidiary I v. NewMarket Pharmaceuticals, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/vetbridge-product-development-subsidiary-i-v-newmarket-pharmaceuticals-mowd-2018.